The Effect of a Psychiatric Nursing Approach Based on the Tidal Model on Psychological Resilience and Self-Compassion Levels in Patients Diagnosed With Anxiety Disorder

August 12, 2026 updated by: Aslı Tekaüt
The purpose of this study is to evaluate the effect of an online psychiatric nursing approach based on the Tidal Model philosophy on the psychological resilience and self-compassion levels of individuals diagnosed with anxiety disorder. The study is designed as a randomized controlled doctoral dissertation. The sample consists of individuals who applied to the psychiatry outpatient clinic of a training and research hospital in Ankara, were diagnosed with anxiety disorder, and met the inclusion criteria. Participants were assigned to either the intervention or control group using a computer-generated randomization method. While the control group received only routine clinical follow-ups without any additional intervention, the intervention group participated in 8 sessions of individual online nursing interventions structured according to Tidal Model principles. Data were collected using an Socio-demographic Information Form, the Psychological Resilience Scale, and the Self-Compassion Scale, administered online to both groups before and after the intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study aims to evaluate the effectiveness of a Tidal Model-based psychiatric nursing intervention in clinical practice and to emphasize the importance of holistic, patient-centered approaches in nursing care for patients with anxiety disorders.

Study Hypotheses:

Hypothesis 1 (H1): The psychological resilience levels of individuals who receive the Tidal Model-based psychiatric nursing approach are statistically significantly higher after the intervention compared to the individuals in the control group.

Hypothesis 2 (H2): The self-compassion levels of individuals who receive the Tidal Model-based psychiatric nursing approach are statistically significantly higher after the intervention compared to the individuals in the control group.

Hypothesis 3 (H3): The psychological resilience levels of individuals in the intervention group show a statistically significant increase after the intervention compared to before the intervention.

Hypothesis 4 (H4): The self-compassion levels of individuals in the intervention group show a statistically significant increase after the intervention compared to before the intervention.

Null Hypothesis (H0): There is no statistically significant difference between the intervention and control groups in terms of psychological resilience and self-compassion levels after the intervention.

Anxiety Disorder, Online Care, Tidal Model, Self-Compassion, Psychological Resilience, Psychiatric Nursing

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
32

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Ankara
      • Ankara, Ankara, Turkey (Türkiye), 06010
        • University of Health Sciences, Gulhane Institute of Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being officially diagnosed with Anxiety Disorder according to DSM-5 diagnostic criteria,
  • Being between 18-65 years of age,
  • Having access to a smartphone, computer, and internet connection sufficient to participate in online sessions,
  • Volunteering to participate in the study and signing the Informed Consent Form.

Exclusion Criteria:

  • Having acute psychosis, bipolar disorder, dementia, or a severe neurological disease in addition to anxiety disorder,
  • Having cognitive or sensory loss that prevents communication, vision, or hearing,
  • Currently participating in another active psychotherapy or psychosocial intervention program simultaneously.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention Group
Participants in this group receive one-on-one online psychiatric nursing interventions based on the Tidal Model, conducted via remote video conferencing. The sessions aim to enable patients to recognize their inner strengths and to increase their psychological resilience and self-compassion levels.
Behavioral: Online Psychiatric Nursing Approach Based on the Tidal Model
One-on-one nursing sessions were conducted via online video conferencing platforms based on the philosophy of the Tidal Model. The intervention involves session processes aligned with the model's domains (Self, World, Partnership) and its ten commitments, enabling patients to construct their own stories, develop anxiety coping skills (psychological resilience), and cultivate a supportive inner voice (self-compassion).
No Intervention: Control Group
Participants in this group did not receive any additional psychosocial or nursing interventions between the dates of completing the pre-test and post-test forms. They completed the process continuing only with their routine clinical psychiatric follow-ups and medical treatments at the healthcare institution where they were registered.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Psychological Resilience Scale Score
Time Frame: Baseline (Week 0, pre-test 1 day before intervention) and Post-test (Week 8, 1 day after completion of the 8-week intervention)
Change in psychological resilience levels as measured by the Resilience Scale for Adults (33 items, 5-point Likert scale). Minimum score is 33 and maximum score is 165. Higher scores indicate higher levels of psychological resilience (better outcome). Pre-test was administered at Week 0 before intervention, and post-test was administered at Week 8 immediately following the 8-week intervention.
Baseline (Week 0, pre-test 1 day before intervention) and Post-test (Week 8, 1 day after completion of the 8-week intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Self-Compassion Scale Score
Time Frame: Baseline (Week 0, pre-test 1 day before intervention) and Post-test (Week 8, 1 day after completion of the 8-week intervention)
Change in self-compassion levels as measured by the Turkish version of the Self-Compassion Scale (Deniz, Kesici, & Sumer, 2008; 24 items, 5-point Likert scale). Minimum score is 24 and maximum score is 120. Higher scores indicate higher levels of self-compassion (better outcome). Pre-test was administered at Week 0 before intervention, and post-test was administered at Week 8 immediately following the 8-week intervention.
Baseline (Week 0, pre-test 1 day before intervention) and Post-test (Week 8, 1 day after completion of the 8-week intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Aslı Tekaüt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 20, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 5, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 5, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 5, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025-462

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings